Epigenomic Remodeling by Lipid Metabolism: A Cross-Disease Perspective on Cancer and Brain Disorders
Open Access
Abstract
Lipid metabolism is no longer viewed simply as a source of membrane biomass or ATP. It is now proposed as a regulatory system that determines which metabolites reach the nucleus, which chromatin-modifying enzymes are engaged, and which transcriptional states become stable during disease progression. This review develops a mechanistic cross-disease framework emphasizing metabolite flux, subcellular compartmentalization, cell-type specificity, and the temporal persistence of chromatin states. We synthesize recent evidence linking lipid metabolism to chromatin remodeling in cancer, Alzheimer’s disease, and Parkinson’s disease, and we highlight how emerging single-cell multi-omics and spatial lipidomics may shape potential metabolism-targeted epigenetic therapies. In both cancer and brain disorders, lipid flux alters the availability of acetyl-CoA, S-adenosylmethionine, NAD+, and bioactive fatty acid derivatives, thereby reshaping histone acetylation, DNA and histone methylation, chromatin accessibility, and transcription-factor activity. In cancer, de novo lipogenesis, acetate scavenging, fatty acid oxidation, and phospholipid remodeling sustain nuclear acetyl-CoA pools, promote oncogenic super-enhancers, and support survival under hypoxia, acidosis, and therapy stress. In neurodegenerative disease, mitochondrial dysfunction, cholesterol dyshomeostasis, sphingolipid imbalance, oxysterol accumulation, and microglial lipid droplet formation may distort the epigenetic programs required for neuronal maintenance, synaptic plasticity, and inflammatory resolution. However, neurodegenerative disorders are not uniformly hypoacetylated; instead, they exhibit stage-, region- and cell-type-specific chromatin remodeling, with hypoacetylation at some vulnerable loci coexisting with hyperacetylation at others. By comparing lipid–epigenome coupling across proliferative and degenerative conditions, we argue that the same metabolic nodes can yield markedly different pathological outcomes depending on cellular context, providing a basis for more precise therapeutic design.Keywords
Funding Information
- Canadian Institutes of Health Research (#450256)
This publication has 161 references indexed in Scilit:
- Lipid dysregulation as a central contributor of neurodegenerative diseases: Emerging therapeutic targets and strategiesAgeing Research Reviews, 2026
- Single‐Cell and Spatial Multiomics: Applications for DiseasesMedcomm, 2025
- Lipid metabolism in cancer stem cells: reprogramming, mechanisms, crosstalk, and therapeutic approachesCellular Oncology, 2025
- Unravelling lipid heterogeneity: Advances in single-cell lipidomics in cellular metabolism and diseaseBBA Advances, 2025
- Acetyl-CoA regulates lipid metabolism and histone acetylation modification in cancerBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2022
- Bile Acids: A Communication Channel in the Gut-Brain AxisNeuroMolecular Medicine, 2020
- Targeting Huntington’s disease through histone deacetylasesClinical Epigenetics, 2011
- Choline and betaine in health and diseaseJournal of Inherited Metabolic Disease, 2010
- Decitabine improves patient outcomes in myelodysplastic syndromesCancer, 2006
- Evidence that accumulation of ceramides and cholesterol esters mediates oxidative stress–induced death of motor neurons in amyotrophic lateral sclerosisAnnals of Neurology, 2002